YPrime Survey Finds 62% of Clinical Site Staff Report eCOA Platforms are Misaligned with Site Needs
25 sept. 2024 09h00 HE
|
Y-Prime, LLC
YPrime releases report on site technology experiences, offering sponsors insights to improve trial efficiency by aligning eCOA platforms with user needs.
YPrime Recognized as Trailblazer in Patient Engagement by Everest Group
24 sept. 2024 08h42 HE
|
Y-Prime, LLC
YPrime has been recognized as a Trailblazer in patient engagement by Everest Group for its innovative solutions that enhance clinical trial participation.
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
24 sept. 2024 08h00 HE
|
Nectero Medical
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
18 sept. 2024 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
18 sept. 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
17 sept. 2024 11h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis &...
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17 sept. 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
16 sept. 2024 07h00 HE
|
Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...